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Although metabolic reprogramming is a hallmark of oncogenic transformation and growth of primary tumor
cells, little is known about how metabolic alterations impact metastasis. In this issue of Cell Metabolism,
Dupuy et al. (2015) show that primary breast cancer cells display metabolic heterogeneity, and that their
distinct metabolic programs define their sites of metastasis.In order to adapt to a reduced oxygen
environment (hypoxia), cancer cells at
the primary tumor site often undergo
reprogramming from oxidative phosphor-
ylation (OXPHOS) to glycolytic meta-
bolism (Vander Heiden et al., 2009). Such
metabolic changes result in increased
glucose consumption and lactate produc-
tion (Warburg effect) and favor growth
and survival of solid tumors. However, it
remained unclear if different metabolic
profiles in primary cancers cells can be
linked to their potential to metastasize,
and also if metabolic signatures exist
that predict the organ site to which can-
cer cells metastasize. Using aggressive
breast cancer as a model system, Dupuy
et al. (2015) now answered both of these
questions by characterizing the intrinsic
metabolic profiles of cancer cells that
spread to different metastatic sites,
including bone, lung, and liver (Figure 1).
When comparing metastatic cell popu-
lations to nonmetastatic cells from the
same parental tumor, Dupuy et al. (2015)
observed a greater oxidative capacity,
as indicated by increased oxygen con-
sumption rate (OCR) and maximal respi-
ration rate. Also correlating with increased
metastatic potential of cells was the abun-
dance of pyruvate after glucose utiliza-
tion. Pyruvate can be used by aerobic
glycolysis and the tricarboxylic acid
(TCA) cycle, and, as shown in this paper,
both metabolic strategies are activated
by metastatic cells with varying degrees
dependent on their site of metastasis.
Distinct populations of cancer cells that
preferentially colonialize to bone, lung, or
liver showed characteristic metabolic
gene expression signatures and differ-
ences in glucose utilization indicated by
measurement of glucose-derived lactate,536 Cell Metabolism 22, October 6, 2015 ª20pyruvate, or citrate. Liver metastatic
breast cancer cells, when compared to
bone or lung metastatic cells, showed
enrichment for glycolytic genes. More-
over, bone and lung metastatic cells,
when compared to liver metastatic cell
or parent cells, displayed increased gluta-
mine uptake and glutamine-derived TCA
cycle intermediates such as citrate and
succinate, while oxidative glutamine
metabolism was reduced in liver metasta-
tic cells. In addition, liver metastatic cells
showed reduced mitochondrial activity
and reactive oxygen species (ROS) pro-
duction, but also exhibited an increase in
reductive carboxylation, suggesting dif-
ferences in carbon flow in this tumor cell
population. A feature of this bifurcation
of metabolic profiles in metastatic cells
was alterations in transcriptional activity
of hypoxia-inducible factor 1a (HIF-1a),
resulting in increased expression of the
gene encoding pyruvate dehydrogenase
kinase (PDK1). PDK1 sets in motion a
glycolytic shift by inactivating pyruvate
dehydrogenase (PDH), which blocks the
conversion of pyruvate to acetyl-CoA
and suppresses the TCA cycle.
Increases in PDK1 expression often
correlate with loss of senescence and
development of cancer (Kaplon et al.,
2013). In primary tumors, activation of
the HIF-1a/PDK1 metabolic switch
allows cancer cells to adapt to hypoxic
conditions and produce energy when
low oxygen does not support OXPHOS,
contributing to tumor cell survival (Kim
et al., 2006). Such PDK1-caused adaptive
metabolic changes to the hypoxic micro-
environment have been shown respon-
sible for poor clinical outcome (Wigfield
et al., 2008), and pharmacological inhibi-
tion of PDK1 increased the response to15 Elsevier Inc.standard cytotoxic chemotherapies due
to an increase in mitochondrial meta-
bolism (Cairns et al., 2007). Dupuy et al.
now show that expression of PDK1 can
drivemetabolic reprogramming that regu-
lates metastasis of breast cancer cells.
The authors found a range of PDK1
expression levels in the parental tumor
cell population, indicating that metabolic
switches influencing tropism of cancer
cells to various metastatic sites already
exist in primary tumors. Of these, cells
with highest PDK1 are subsequently
selected for colonialization of the liver,
and depletion of PDK1 led to a signifi-
cant reduction in the metastatic burden
in the liver without affecting lung metas-
tasis. Supporting their findings derived
from mouse models, Dupuy et al. also
demonstrated that PDK1 expression
was elevated in liver metastases, but not
in skin metastases, in breast cancer
patients.
In the present paper, not only did
Dupuy et al. (2015) find that different
metabolic strategies are used with vary-
ing degrees dependent on metastatic
potential and site of metastasis, they
also showed that metastatic breast can-
cer cells retain their metabolic pheno-
type following colonialization to the liver.
Thus, metabolic differences caused by
increased expression of PDK1 also
seem to be important for adaptation of
breast cancer cells to the microenvi-
ronment in the target organ, which may
include a crosstalk with normal cells.
For example, in the liver, hepatocytes
may take up tumor-cell-derived lactate
to convert it into metabolites that could
help metastatic cancer cells fuel their
growth, as observed in other cancers
(Nieman et al., 2011).
Figure 1. Variations in Their Metabolic Program Target Primary
Breast Cancer Cells to Different Metastatic Sites
Primary breast cancer cells, dependent on their metastatic potential (blue
cells, low metastatic potential; red/yellow cells, high metastatic potential),
show alterations in their metabolic profile that can be associated with site-
specific metastasis. For example, breast cancer cells that metastasize to the
liver (red cells) are dependent on glycolysis, while bone- and lung-metastatic
cells (yellow cells) engage OXPHOS. Cells that engage both OXPHOS and
glycolysis show a broader metastatic potential. Such specific metabolic
changes may allow crosstalk of metastatic cells with normal cells in the target
organ and provide a growth advantage.
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metastatic cells are using to
switch to glycolysis remain
to be discovered. Metabolic
pathways can change in
response to acquired muta-
tions and environmental cues,
such as the loss of PTEN-
induced kinase 1 (PINK1),
which has been shown to
destabilize HIF-1a (Requejo-
Aguilar et al., 2014). Another
possible mechanism may be
activation of altered Wnt/
b-catenin signaling known to
promote glycolysis in colon
cancer, also by targeting
PDK1. In this context, WNT/
PDK1-driven glycolytic meta-
bolism induces vessel growth
in the tumor microenviron-
ment, facilitating delivery of
oxygen and nutrients (Pate
et al., 2014). It alsowill be inter-
esting to see if other meta-
bolic regulators associated
with HIF-1a, such as PDK3
and PKM2 (pyruvate kinase
isoform M2), are dysregulated
in metastatic cancer cells and
if this also contributes to
dissemination or seeding to
specific organs.
Since the Warburg effect
can be triggered by mito-
chondrial damage and result
in increased resistance of tu-
mor cells to oxidative stress,
it is possible that subpopula-
tions in the primary tumor
site use this metabolic strat-
egy to become increasinglymotile and seed organs providing bet-
ter growth conditions. For example,
loss of the respiratory enzyme citrate
synthase (CS) directly links the Warburg
effect to tumor malignancy, and its
knockdown can induce morphological
changes characteristic of epithelial-to-mesenchymal transition (EMT), acceler-
ating cancer cell metastasis (Lin et al.,
2012).
In summary, the importance of the find-
ings presented by Dupuy et al. (2015) is
that they demonstrate that primary can-
cer cells can show heterogeneity in theirCell Metabolism 22, October 6metabolic programs that
dictate to which organ site
cancer cells will colonize.
The understanding of such
divergent metabolic profiles
offers unique opportunities
for targeted treatment or pre-
vention of metastases.REFERENCES
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